This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katragkou, A.
Right arrow Articles by Roilides, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katragkou, A.
Right arrow Articles by Roilides, E.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2005, p. 4916-4917, Vol. 43, No. 9
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.9.4916-4917.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Successful Treatment of Multidrug-Resistant Acinetobacter baumannii Central Nervous System Infections with Colistin


arrow
LETTER
 
Acinetobacter baumannii may cause severe central nervous system (CNS) infections, such as meningitis and ventriculitis, especially in patients undergoing neurosurgical procedures or head trauma. Mortality ranges from 20% to 27% in different case series (3). Carbapenems have been considered the treatment of choice for severe infections. However, increasing numbers of carbapenem-resistant Acinetobacter isolates have been reported worldwide, dramatically reducing the existing therapeutic options (1).

Over the past 30 years, colistin use has been limited due to concerns regarding its toxicity along with the development of newer antibiotics with better safety profiles (5, 7). However, the increasing incidence of multidrug-resistant A. baumannii in addition to a lack of new antimicrobial agents has reawakened interest in the utilization of colistin due to its good activity against this organism (7).

Although of particular interest, reports on the management of CNS infections due to multidrug-resistant A. baumannii with colistin are relatively scarce. In order to build on this experience, we reviewed the literature and summarized the up-to-date data. Reports for this review were found through a search of PubMed and of references cited in relevant articles. To the best of our knowledge, eight reports (one prospective nonrandomized study [11], one retrospective study [4], and six case reports [2, 6, 8-10, 13]) overall have been published. These include a total of 14 patients who suffered from CNS infection (meningitis or ventriculitis) due to multidrug-resistant A. baumannii and were treated with colistin intravenously and/or either intrathecally or intraventricularly (Table 1).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Reported cases of multidrug-resistant A. baumannii CNS infections treated with colistin

In none of these cases was treatment discontinued due to adverse effects; however, some authors emphasized the need of dose modification, especially in patients with renal insufficiency (11). Although nephrotoxicity, neurotoxicity, and neuromuscular blockage have been described in association with systemic use of colistin (5), in the reports reviewed here intrathecal or intraventricular administration exhibited a safe profile even after prolonged use. Generally, intrathecal or intraventricular administration of colistin alone or in combination with systematic administration was well tolerated and could be an effective salvage therapy in patients with CNS infections due to A. baumannii strains resistant to conventional antibiotics. It is of note that sterilization of cerebrospinal fluid (CSF) was achieved in all reported cases within a median of 4.5 days (range 1 to 6 days). Moreover, cure was achieved in all but one case reported (13 out of 14 cases; cure rate, 93%).

By using a broth dilution assay of polymyxins, Jimenez-Mejias et al. determined that about 25% of colistin penetrated the CSF and reached bactericidal concentrations for the entire dosing period. Colistin produced a peak of 5 µg/ml in serum and a peak of 1.25 µg/ml in CSF 1 h after intravenous administration (8, 9). To date it is well known that colistin methanesulfonate, once administered, is hydrolyzed to a mixture of products (colistin sulfate or base, which is more microbiologically active, and its partially sulfomethylated derivatives). Therefore, microbiological assays lack specificity, since the concentrations quantified are apparent values for the combined antibacterial activity of the mixture of hydrolytic products of colistin methanesulfonate (12).

From this analysis it becomes evident that, indeed, experience in multidrug-resistant Acinetobacter CNS infections is scattered. Besides, some of the existing reports provide inadequate information to come to safe conclusions. Consequently, more extensive pharmacokinetic and pharmacodynamic studies as well as randomized controlled trials are needed to evaluate the clinical use of colistin and the desirable concentrations in CSF after intravenous administration.


arrow
REFERENCES
 
    1
  1. Afzal-Shah, M., and D. M. Livermore. 1998. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J. Antimicrob. Chemother. 41:576-577.[Free Full Text]
    2. 2
  2. Benifla, M., G. Zucker, A. Cohen, and M. Alkan. 2004. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J. Antimicrob. Chemother. 54:290-292.[Free Full Text]
    3. 3
  3. Bergogne-Berezin, E., and K. J. Towner. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9:148-165.[Medline]
    4. 4
  4. Berlana, D., J. M. Llop, E. Fort, M. B. Badia, and R. Jodar. 2005. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am. J. Health Syst. Pharm. 62:39-47.[Abstract/Free Full Text]
    5. 5
  5. Evans, M. E., D. J. Feola, and R. P. Rapp. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 33:960-967.[Abstract]
    6. 6
  6. Fernandez-Viladrich, P., X. Corbella, L. Corral, F. Tubau, and A. Mateu. 1999. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin. Infect. Dis. 28:916-917.[Medline]
    7. 7
  7. Jain, R., and L. H. Danziger. 2004. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann. Pharmacother. 38:1449-1459.[Abstract/Free Full Text]
    8. 8
  8. Jimenez-Mejias, M. E., B. Becerril, F. J. Marquez-Rivas, C. Pichardo, L. Cuberos, and J. Pachon. 2000. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur. J. Clin. Microbiol. Infect. Dis. 19:970-971.[CrossRef][Medline]
    9. 9
  9. Jimenez-Mejias, M. E., C. Pichardo-Guerrero, F. J. Marquez-Rivas, D. Martin-Lozano, T. Prados, and J. Pachon. 2002. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 21:212-214.[CrossRef][Medline]
    10. 10
  10. Kasiakou, S. K., P. I. Rafailidis, K. Liaropoulos, and M. E. Falagas. 2005. Cure of post-traumatic recurrent multiresistant gram-negative rod meningitis with intraventricular colistin. J. Infect. 50:348-352.[CrossRef][Medline]
    11. 11
  11. Levin, A. S., A. A. Barone, J. Penco, M. V. Santos, I. S. Marinho, E. A. Arruda, E. I. Manrique, and S. F. Costa. 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28:1008-1011.[Medline]
    12. 12
  12. Li, J., R. L. Nation, R. W. Milne, J. D. Turnidge, and K. Coulthard. 2005. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25.[CrossRef][Medline]
    13. 13
  13. Vasen, W., P. Desmery, S. Ilutovich, and A. Di Martino. 2000. Intrathecal use of colistin. J. Clin. Microbiol. 38:3523.[Free Full Text]
Aspasia Katragkou
Emmanuel Roilides*
Laboratory of Infectious Diseases
3rd Department of Pediatrics
Aristotle University
Hippokration Hospital
Thessaloniki 54642, Greece

* Phone: 30-2310-892444, Fax: 30-2310-992983, E-mail: roilides{at}med.auth.gr

Journal of Clinical Microbiology, September 2005, p. 4916-4917, Vol. 43, No. 9
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.9.4916-4917.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., Bonomo, R. A. (2007). Global Challenge of Multidrug-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 3471-3484 [Full Text]  
  • Tan, C.-H., Li, J., Nation, R. L. (2007). Activity of Colistin against Heteroresistant Acinetobacter baumannii and Emergence of Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrob. Agents Chemother. 51: 3413-3415 [Abstract] [Full Text]  

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katragkou, A.
Right arrow Articles by Roilides, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katragkou, A.
Right arrow Articles by Roilides, E.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»